X0508 4 2025-01-27 0000842023 BIO-TECHNE Corp TECH 0001739054 Kelderman Kim 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413 1 1 0 0 Chief Executive Officer 0 Common Stock 2025-01-27 4 M 0 13392 37.70 A 52396 D Common Stock 2025-01-27 4 S 0 11731 77.1915 D 40665 D Common Stock 2025-01-27 4 S 0 1661 77.9530 D 39004 D Stock Option (Right to Buy) 37.70 2025-01-27 4 M 0 13392 0 D 2025-05-01 Common Stock 13392 0 D Stock Option (Right to Buy) 44.33 2025-08-08 Common Stock 84308 84308 D Stock Option (Right to Buy) 47.60 2026-08-07 Common Stock 109536 109536 D Stock Option (Right to Buy) 66.97 2027-08-05 Common Stock 115724 115724 D Stock Option (Right to Buy) 120.46 2028-08-06 Common Stock 25944 25944 D Performance Restricted Stock Units Common Stock 6984 6984 D Performance Stock Options (Right to Buy) 94.52 2029-08-15 Common Stock 21704 21704 D Stock Options (Right to Buy) 94.52 2029-08-15 Common Stock 28940 28940 D Performance Restricted Stock Units Common Stock 8873 8873 D Performance Stock Options (Right to Buy) 84.61 2030-08-15 Common Stock 23881 23881 D Stock Options (Right to Buy) 84.61 2030-08-15 Common Stock 29391 29391 D Stock Options (Right to Buy) 52.83 2030-11-01 Common Stock 38252 38252 D Performance Restricted Stock Units Common Stock 9423 9423 D Performance Stock Options (Right to Buy) 68.54 2031-02-01 Common Stock 25945 25945 D Stock Options (Right to Buy) 68.54 2031-02-01 Common Stock 51890 51890 D Performance Restricted Stock Units Common Stock 51261 51261 D Restricted Stock Units Common Stock 25630 25630 D Stock Options (Right to Buy) 74.91 2034-08-15 Common Stock 69061 69061 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.69 to $78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Fully exercisable. Options to purchase 6,484 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 6,488 shares vest on each of 8/6/2024 and 8/6/2025. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. /s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed. 2025-01-29